Last updated on April 16, 2014 at 5:31 EDT

Cardiome Announces Commercialization Partnership For BRINAVESS(TM) In Select European Markets

July 3, 2013


VANCOUVER, July 3, 2013 /PRNewswire/ – Cardiome Pharma Corp. (NASDAQ: CRME /
TSX: COM) today announced an agreement with AOP Orphan Pharmaceuticals
AG, headquartered in Vienna, Austria, to commercialize BRINAVESS(TM)
(vernakalant intravenous) in select European markets. AOP Orphan will
support Cardiome in obtaining product registrations required for the
marketing and sale of BRINAVESS in the AOP Orphan countries and will
actively call on customers to promote the product.  Under terms of the
agreement, AOP Orphan has agreed to specific annual commercial goals
for BRINAVESS. Financial details of the agreement were not disclosed.

“Execution of the BRINAVESS commercial agreement with AOP Orphan
fulfills a key objective in Cardiome’s European commercialization
strategy,” said William Hunter, M.D., CEO of Cardiome. “Through the
agreement, additional physicians and patients beyond the reach of our
current sales force will have access to BRINAVESS. We are very pleased
to have partnered with such a well-known, highly experienced and
respected company.”

“We are excited to partner and work with Cardiome, and to add BRINAVESS
to our cardiovascular drug portfolio,” said Rudolf Widmann, Ph. D., CEO
of AOP Orphan. “The synergies that exist between BRINAVESS and our
cardiovascular franchise should enable us to build on our existing
customer base by offering a complementary product and develop new
customer relationships which are key to our future growth.”

The initial term of this commercial agreement begins July 1, 2013 for
the duration of three years and is renewable on an annual basis, or
longer, thereafter. The AOP Orphan countries include: Austria; Bosnia
and Herzegovina; Bulgaria; Croatia; Czech Republic; Estonia; Hungary;
Kazakhstan; Latvia; Lithuania; Montenegro; Macedonia; Poland; Romania;
Serbia; Slovakia; Slovenia; Switzerland; and Ukraine.

About Cardiome Pharma Corp.

Cardiome Pharma Corp. is a biopharmaceutical company dedicated to the
discovery, development and commercialization of new therapies that will
improve the health of patients around the world. Cardiome has one
marketed product, BRINAVESS(TM) (vernakalant IV), approved in Europe and
other territories for the rapid conversion of recent onset atrial
fibrillation to sinus rhythm in adults.

Cardiome is traded on the NASDAQ Capital Market (CRME) and the Toronto
Stock Exchange (COM). For more information, please visit our web site
at www.cardiome.com.

Forward-Looking Statement Disclaimer

Certain statements in this news release contain forward-looking
statements within the meaning of the Private Securities Litigation
Reform Act of 1995 or forward-looking information under applicable
Canadian securities legislation that may not be based on historical
fact, including without limitation statements containing the words
“believe”, “may”, “plan”, “will”, “estimate”, “continue”, “anticipate”,
“intend”, “expect” and similar expressions.  Forward- looking
statements may involve, but are not limited to, comments with respect
to our objectives and priorities for the remainder of 2013 and beyond,
our strategies or future actions, our targets, expectations for our
financial condition and the results of, or outlook for, our operations,
research and development and product and drug development. Such
forward-looking statements involve known and unknown risks,
uncertainties and other factors that may cause the actual results,
events or developments to be materially different from any future
results, events or developments expressed or implied by such
forward-looking statements. Many such known risks, uncertainties and
other factors are taken into account as part of our assumptions
underlying these forward-looking statements and include, among others,
the following: general economic and business conditions in the United
States, Canada, Europe, and the other regions in which we operate;
market demand; technological changes that could impact our existing
products or our ability to develop and commercialize future products;
competition; existing governmental legislation and regulations and
changes in, or the failure to comply with, governmental legislation and
regulations; availability of financial reimbursement coverage from
governmental and third-party payers for products and related
treatments; adverse results or unexpected delays in pre-clinical and
clinical product development processes; adverse findings related to the
safety and/or efficacy of our products or products; decisions, and the
timing of decisions, made by health regulatory agencies regarding
approval of our technology and products; the requirement for
substantial funding to expand commercialization activities; and any
other factors that may affect our performance. In addition, our
business is subject to certain operating risks that may cause any
results expressed or implied by the forward-looking statements in this
presentation to differ materially from our actual results. These
operating risks include: our ability to attract and retain qualified
personnel; our ability to successfully complete pre-clinical and
clinical development of our products; changes in our business strategy
or development plans; intellectual property matters, including the
unenforceability or loss of patent protection resulting from
third-party challenges to our patents; market acceptance of our
technology and products; our ability to successfully manufacture,
market and sell our products; the availability of capital to finance
our activities; and any other factors described in detail in our
filings with the Securities and Exchange Commission available at www.sec.gov and the Canadian securities regulatory authorities at www.sedar.com. Given these risks, uncertainties and factors, you are cautioned not to
place undue reliance on such forward-looking statements and
information, which are qualified in their entirety by this cautionary
statement. All forward-looking statements and information made herein
are based on our current expectations and we undertake no obligation to
revise or update such forward-looking statements and information to
reflect subsequent events or circumstances, except as required by law.

SOURCE Cardiome Pharma Corp.

Source: PR Newswire